Journal of Clinical and Translational Hepatology

Journal of Clinical and Translational Hepatology

Wednesday, 06 / 16 / 2021



Review of Clinically Relevant Drug Interactions with Next Generation Hepatitis C Direct-acting Antiviral Agents

Jenny Hong#,1, Robert C. Wright#,1, Nilu Partovi1,2, Eric M. Yoshida3,4 and Trana Hussaini*,1,2,3 

1  Pharmaceutical Sciences, Vancouver General Hospital, Vancouver, BC, Canada
2  Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada
3  Liver Transplant Program, Vancouver General Hospital, Vancouver, BC, Canada
4  Division of Gastroenterology, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada
#These authors contributed equally to this work.
*Correspondence to: Trana Hussaini, Pharmaceutical Sciences Clinical Service Unit, Vancouver General Hospital, 855 West 12th Ave, Vancouver, BC V5Z 1M9, Canada. Tel: +1-604-875-4077, Fax: +1-604-875-5267, E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Journal of Clinical and Translational Hepatology 2020;8(3):322-335 DOI: 10.14218/JCTH.2020.00034
Received: April 19, 2020 Accepted: June 30, 2020 Published onlineJuly 30, 2020


In this review, we examine the pharmacokinetics and clinically relevant drug interactions of the newer generation direct-acting antivirals (DAAs) for the treatment of chronic hepatitis C, specifically sofosbuvir/velpatasvir (Epclusa®), sofosbuvir/velpatasvir/voxilaprevir (Vosevi®), glecaprevir/pibrentasvir (Maviret®), and elbasvir/grazoprevir (Zepatier®). We searched MEDLINE (1948-January 2020), Embase (1964-January 2020), Google, and GoogleScholar using the terms pharmacokinetics, drug interaction, drug metabolism, sofosbuvir, velpatasvir, Epclusa, voxilaprevir, Vosevi, glecaprevir, pibrentasvir, Maviret, elbasvir, grazoprevir, and Zepatier, from inception to January 13, 2020. The search was limited to randomized controlled trials, in vitro studies, prospective and retrospective human studies, drug monographs, abstracts, and conference proceedings. All relevant published literature on pharmacokinetic and pharmacodynamic interactions involving DAAs were reviewed and the data extracted. Numerous clinically relevant drug-drug interactions (DDIs) were identified with the newer generation DAAs and commonly prescribed drugs. NS3/4A protease inhibitors are more likely to be involved in DDIs, followed by NS5A inhibitors and NS5B polymerase inhibitor. The majority of clinically relevant DDIs are predictable, according to known pharmacokinetic, pharmacodynamics, and physicochemical properties of DAAs; however, in select cases, unpredictable DDIs do occur. As expected, many drug interactions exist between newer generation DAAs and commonly prescribed medications. While the majority of clinically relevant interactions are predictable, many require therapeutic dose adjustment or careful selection of non-interacting drugs. In select cases, severe and unpredictable drug interactions can occur. Clinicians should consult hepatitis C virus pharmacotherapy experts and tertiary drug interaction resources when initiating DAA therapy in patients taking other medications.


Hepatitis C, Drug interactions, Pharmacokinetics, Direct-acting antiviral agents

Journal of Clinical and Translational Hepatology 2020 vol. 8, 322-335  [ Html  ] [ PDF Full-text ]

© The Authors 2020. This article is published under the terms of the Creative Commons Attribution-Noncommercial License (CC BY-NC 4.0), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.


You are here: Home